High Levels of Circulating Hematopoietic Progenitor Cells after Continuous Infusion of High Dose Interleukin-2 in Cancer Patients

  • M. R. Schaafsma
  • J. H. F. Falkenburg
  • N. Duinkerken
  • D. van der Harst
  • A. Brand
  • S. Osanto
  • C. R. Franks
  • R. Willemze
  • W. E. Fibbe
Part of the Developments in Hematology and Immunology book series (DIHI, volume 25)


Over the past few years recombinant human interleukin-2 (IL-2), with or without infusion of in vitro generated lymphokine-activated killer (LAK) cells, has been administered to patients with disseminated cancer for its antitumor activity [1]. It has been demonstrated that this treatment is accompanied by various hematologic side effects, including anemia, thrombocytopenia, eosinophilia and lymphopenia, followed by a rebound lymphocytosis after discontinuation of IL-2 infusion [2,3]. Little is known, however, about the effects of IL-2 administration on the in vivo proliferation of hematopoietic progenitor cells (HPC). In mice, Talmadge et al [4] showed that the number of myeloid progenitor cells (CFU-GM) in bone marrow increased during IL-2 treatment, probably secondary to the induction of GM-CSF and IL-3. In humans, Ettinghausen et al [3] reported decreased numbers of circulating HPC during IL-2 treatment, suggesting an inhibitory effect of IL-2 on hematopoiesis. One of the patients in their study, however, showed a strong increase in the number of circulating progenitor cells after discontinuation of IL-2 therapy.


Peripheral Blood Stem Cell Hematopoietic Progenitor Cell Autologous Transplantation Hemopoietic Stem Cell Autologous Peripheral Blood Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Im- munol 1985;135:2865–75.Google Scholar
  3. 3.
    Ettinghaussen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-acti- vated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987;69:1654–60.Google Scholar
  4. 4.
    Talmadge JE, Schneider M, Keller J, et al. Myelostimulatory activity of recombinant human interleukin-2 in mice. Blood 1989;73:1458–67.PubMedGoogle Scholar
  5. 5.
    Körbling M, Fliedner TM, Pflieger H. Collection of large quantities of granulocyte/macrophage progenitor cells (CFU-C) in man by means of con- tinuous-flow leukapheresis. Scand J Haematol 1980;24:22–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Barber KE, Crosier PS, Gillis S, Watson JD. Human granulocyte-macrophage progenitors and their sensitivity to cytotoxins: Analysis by limiting dilution. Blood 1987;70:1773–6.PubMedGoogle Scholar
  7. 7.
    Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983;131:1300–5.PubMedGoogle Scholar
  8. 8.
    Körbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 1986;67:529–32.PubMedGoogle Scholar
  9. 9.
    Reiffers J, Bernard P, David B, et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986;14:312–5.PubMedGoogle Scholar
  10. 10.
    Bell AJ, Figes A, Oscier DG, Hamblin TJ. Peripheral blood stem cell auto-grafts in the treatment of lymphoic malignancies: Initial experience in three patients. Br J Haematol 1987;66:63–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Castaigne S, Calvo F, Douay L, et al. Successful hematopoietic reconstitution using autologous peripheral blood mononuclear cells in a patient with acute promyelocytic leukemia (letter). Br J Haematol 1986;63:209–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Tilly H, Bastit D, Lucet J-C, Esperou H, Monconduit M, Piguet H. Hemo-poietic reconstitution after autologous peripheral blood stem cell trans- plantation in acute leukemia (letter). Lancet 1986;ii:154–5.CrossRefGoogle Scholar
  13. 13.
    Fermand J-P, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20–3.PubMedGoogle Scholar
  14. 14.
    Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031–9.PubMedGoogle Scholar
  15. 15.
    To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating hemopoietic stem cells in very early remission from acute non-lympho-blastic leukemia and their collection and cryopreservation. Br J Haematol 1984;58:399–410.PubMedCrossRefGoogle Scholar
  16. 16.
    To LB, Juttner CA. Peripheral blood stem cell autografting: A new therapeutic option for AML? Br J Haematol 1987;66:285–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • M. R. Schaafsma
  • J. H. F. Falkenburg
  • N. Duinkerken
  • D. van der Harst
  • A. Brand
  • S. Osanto
  • C. R. Franks
  • R. Willemze
  • W. E. Fibbe

There are no affiliations available

Personalised recommendations